EICHORPublic-registry site landscape for NCT04596631, “A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes”, a Diabetes Mellitus, Type 2 study sponsored by Novo Nordisk A/S. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04596631 (registry record) |
| Study title | A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes |
| Official title | Efficacy and Safety of Oral Semaglutide Versus Placebo Both in Combination With Metformin and/or Basal Insulin in Children and Adolescents With Type 2 Diabetes |
| Sponsor | Novo Nordisk A/S |
| Condition(s) | Diabetes Mellitus, Type 2 |
| Phase | PHASE3 |
| Listed sites | 97 |
| Site countries | United States, Australia, Austria, Belgium, Czechia, Greece, India, Israel, Lebanon, Malaysia, Mexico, Morocco |
Patient-friendly overview of this study: eichor.com/study/NCT04596631.
Eichor generates a preliminary site-risk snapshot for NCT04596631 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetes Mellitus, Type 2 trials
More from Novo Nordisk A/S
← Eichor home · All tracked trials · Diabetes Mellitus, Type 2 studies · Weekly briefs
